ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis

Betty Schwartz, Oded Shoseyov, Vladislava O. Melnikova, Marya McCarty, Michael Leslie, Levava Roiz, Patricia Smirnoff, Guo Fu Hu, Dina Lev, Menashe Bar-Eli

Research output: Contribution to journalArticlepeer-review

Abstract

Melanoma is a very aggressive and highly angiogenic tumor in which standard treatments have had only limited success. Patients with advanced disease have a 5-year survival rate of 5%. In search for alternatives, we identified a natural product extracted from the fungus Aspergillus niger, termed ACTIBIND, that inhibits tumor growth and metastasis of melanoma in vivo. ACTIBIND, a T 2 RNase, exerts antitumorigenic and antiangiogenic activities by competing with the angiogenic factor angiogenin (itself an RNase homologue). Thus, there was decreased expression and activity of the matrix metalloproteinase 2 in melanoma and vascular endothelial cells, decreased vascularization, and increased tumor cell apoptosis in vivo. ACTIBIND significantly inhibited angiogenesis in an in vivo angiogenesis assay with sponges containing angiogenin. In vitro, ACTIBIND was internalized by both melanoma and human umbilical vein endothelial cells, reached the cell nuclei, and inhibited the activity of angiogenin response elements in a dose-dependent manner. Collectively, our data indicate that ACTIBIND should be tested for its potential as a new antiangiogenic modality for the treatment of melanoma.

Original languageEnglish
Pages (from-to)5258-5266
Number of pages9
JournalCancer Research
Volume67
Issue number11
DOIs
StatePublished - 1 Jun 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis'. Together they form a unique fingerprint.

Cite this